Speakers - Sachs Associates

CONTACTS
Carlos Buesa
Chief Executive Officer
Emili Torrell
Business Development Officer
ADDRESS
C/San Ferran 74
08940 Cornella de Llobregat
(Barcelona), SPAIN
TELEPHONE
+34 93 515 13 13
FAX
+34 93 377 40 28
EMAIL
cbuesa@oryzon.com
etorrell@oryzon.com
info@oryzon.com
YEAR FOUNDED
2000
ORYZON
www.oryzon.com
FINANCIAL SUMMARY
Stage of funding
5 Funding rounds from inception (15 M€ in total) + 15 M€ in Competitive Grants. Last funding (9M€) was
accomplished in 2008. These funds were also matched with a set of competitive grants and long-term / nullvery
soft rates public loans.
Capital plans – IPO plans
The Company will need a new round of funding (8-10M) in late 2012 early 2013 to keep the development of the
programs to Phase I-II in full speed. The company is considering to get this funding either through C series or
preIPO funding.
Investors. The company has a French-Spanish VC firm NAJETI as main stakeholder from 2003. Other VCs
having minor stakes are CORSABE, Invercat and Barcelona Empren. Several Spanish family offices and private
minor investors are also present.
COMPANY PROFILE
Oryzon is a biomarker discovery company with a dual therapeutic pipeline in oncology and neurodegeneration.
Founded in 2000, and venture backed from 2002, Oryzon has a strong focus in EPIGENETIC TARGETS with a
special emphasis in Histone Lysine Demethylases being a global leader on Lysine Specific Demethylase-1 with
a dominant IP position. LSD1 has been proposed as a target for oncology, viral diseases and neurodegeneration.
Oryzon has two preclinical programs with different preclinical candidates LSD1i, one in ACUTE MIELOGENOUS
LEUKAEMIA and the other in Huntington disease. Our inhibitors are highly potent in vitro (low nM) and in
vivo (